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Noradrenergic neurons in the locus coeruleus (LC) are significantly reduced in Parkin-
son’s disease (PD) and the LC exhibits neuropathological changes early in the disease
process. It has been suggested that a loss of LC neurons can enhance the suscepti-
bility of dopaminergic neurons to damage. To determine if LC noradrenergic innervation
protects dopaminergic neurons from damage, the dopaminergic neurotoxin 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) was administered to adult male C57Bl/6 mice
3 days after bilateral LC administration of 6-hydroxydopamine (6OHDA), a time when there
is a significant reduction in LC neuronal number and innervation to forebrain regions. To
assess if LC loss can affect dopaminergic loss four groups of animals were studied: control,
6OHDA, MPTP, and 6OHDA+MPTP; animals sacrificed 3 weeks after MPTP administra-
tion.The number of dopaminergic neurons in the substantia nigra (SN) and ventral tegmen-
tal area (VTA), and noradrenergic neurons in the LC were determined. Catecholamine levels
in striatum were measured by high-pressure liquid chromatography.The loss of LC neurons
did not affect the number of dopaminergic neurons in the SN and VTA compared to con-
trol; however, LC 6OHDA significantly reduced striatal dopamine (DA; 29% reduced) but
not norepinephrine (NE) concentration. MPTP significantly reduced SN and VTA neuronal
number and DA concentration in the striatum compared to control; however, there was
not a correlation of striatal DA concentration with SN or VTA neuronal number. Adminis-
tration of 6OHDA prior to MPTP did not enhance MPTP-induced damage despite an effect
of LC loss on striatal DA concentration. However, the loss of LC neurons before MPTP
resulted now in a correlation between SN and VTA neuronal number to striatal DA concen-
tration. These results demonstrate that the loss of either LC or DA neurons can affect the
function of each others systems, indicating the importance of both the noradrenergic and
dopaminergic system in PD.
Keywords: 6-hydroxydopamine, MPTP, locus coeruleus, substantia nigra, ventral tegmentum area, catecholamines,
striatum
INTRODUCTION
Parkinson’s disease (PD) is a neurological disorder that is char-
acterized by various motor deficits including tremor, rigidity, and
bradykinesia (Singh et al., 2007). The cause of these motor symp-
toms is the loss of dopaminergic neurons in the substantia nigra
(SN) pars compacta and subsequently reduced dopamine (DA)
concentration in the striatum (Gibb, 1991; Gibb and Lees, 1991;
Damier et al., 1999). The cause of dopaminergic neuronal loss in
PD is still unknown. However, dopaminergic neurons are not the
only neurons reduced in PD. Locus coeruleus (LC) noradrenergic
neurons are also significantly reduced in PD; the loss of LC neu-
rons is equal to or greater than the loss of dopaminergic neurons
in the SN (Cash et al., 1987; Hornykiewicz and Kish, 1987; Chan-
Palay and Asan, 1989; Patt and Gerhard, 1993; Bertrand et al.,
1997; Zarow et al., 2003; McMillan et al., 2011). Neuropathological
changes associated with PD appear in the LC before the appearance
in dopaminergic neurons (Braak et al., 2003, 2006). The midbrain
dopaminergic neurons in the SN and ventral tegmental area (VTA)
receive direct innervation from LC noradrenergic neurons (Swan-
son and Hartman, 1975; Jones and Moore, 1977; Phillipson, 1979;
Simon et al., 1979; Jones and Yang, 1985; Fritschy and Grzanna,
1990; Szot et al., 2012). A reduction in LC noradrenergic activity
results in reduced activity of SN and VTA neurons (Grenhoff and
Svensson, 1989, 1993; Grenhoff et al., 1993, 1995; Guiard et al.,
2008; Wang et al., 2010) and dopamine-induced behavior (Antel-
man and Caggiula, 1977; Chopin et al., 1999; Rommelfanger et al.,
2007; Grimbergen et al., 2009; Taylor et al., 2009; Wang et al., 2010).
If the noradrenergic nervous system experiences a disruption in
function before the dopaminergic system in PD (Braak et al., 2003,
2006) and the noradrenergic nervous system directly innervates
dopaminergic neurons in the SN and VTA, a loss of noradrenergic
neurons could increase the susceptibility of dopaminergic neurons
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to damage in the progression of PD. There are several studies
suggesting that the administration of a noradrenergic neurotoxin
prior to the application of a dopaminergic neurotoxin will enhance
the susceptibility of dopaminergic neurons to damage (Mavridis
et al., 1991; Marien et al., 1993; Bing et al., 1994; Fornai et al.,
1995, 1996, 1997; Srinivasan and Schmidt, 2003, 2004; Archer and
Fredriksson, 2006). However, these studies are not comprehensive
and some used N -(2-chloroethyl)-N -ethyl-2-bromobenzylamine
(DSP4) as the noradrenergic neurotoxin. DSP4 produces a rapid
though transient reduction in terminal norepinephrine (NE) con-
centration in specific forebrain regions (Ross, 1976; Jonsson et al.,
1981; Grzanna et al., 1989; Theron et al., 1993; Wolfman et al.,
1994; Kask et al., 1997; Hughes and Stanford, 1998; Szot et al.,
2010). However, there are data specifically in rats indicating that
DSP4 does not result in a loss of LC noradrenergic neurons, sug-
gesting neuronal loss is not to account for the changes observed in
noradrenergic forebrain markers (Booze et al., 1988; Lyons et al.,
1989; Robertson et al., 1993; Matsukawa et al., 2003; Szot et al.,
2010).
Recent work in our laboratory has shown that direct adminis-
tration of 6-hydroxydopamine (6OHDA) into the LC will specifi-
cally reduce LC noradrenergic neurons, resulting in a reduction of
NE concentration and NE transporter (NET) in forebrain regions
3 weeks later (Szot et al., 2012). The changes in noradrenergic
forebrain markers produced by 6OHDA are different from the
changes produced by DSP4 (Szot et al., 2012), suggesting that
these two neurotoxins result in different responses of noradrener-
gic neurons. Therefore, the objective of this study is to determine
if the loss of LC noradrenergic neurons induced by LC adminis-
tration of 6OHDA prior to the administration of the dopamin-
ergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) enhances the susceptibility of dopaminergic neurons in
the SN and VTA to damage, and further decrease DA concentra-
tion in the striatum. MPTP is administered 3 days after bilateral
6OHDA administration directly into the LC, a time similar to pre-
viously published work (Mavridis et al., 1991; Marien et al., 1993;
Fornai et al., 1995, 1996, 1997; Srinivasan and Schmidt, 2003,
2004). The number of LC, SN, and VTA neurons is assessed as
well as the amount of DA and other catecholamines in the stria-
tum. Correlations of neuronal loss in each treatment group are
measured against concentration of catecholamines in the striatum.
MATERIALS AND METHODS
ANIMALS
Experiment 1: 3-day 6OHDA study
Thirty adult male C57Bl/6 mice were purchased from Charles
River Laboratories (Wilmington, MA, USA) and housed in stan-
dard enriched environment cages in a temperature controlled
room with a 12-h light/dark cycle. Food and water were provided
ad libitum. The animals were given at least 2 weeks acclimating
period in the facility before administration of 6OHDA. All animal
procedures were in accordance with the Animal Care Committee
at the VA Puget Sound Health Care System, Seattle, WA, USA, and
National Institute of Health guidelines. The minimum number of
animals was used for these studies and care was taken to minimize
any suffering. Sixteen mice were administered 6OHDA (10µg/µl)
and 14 mice were administered vehicle (0.2% ascorbic acid/saline)
bilaterally into the LC as previously described (Szot et al., 2010).
Animals were sacrificed 3 days later, and brains removed. The hind-
brain portion containing the LC and lateral tegmental regions
was dissected free and cut on a cryostat at 16µm onto Super-
frost Plus slides (Fisher Scientific, Pittsburgh, PA, USA) into three
sets consisting of alternating sections and stored at −80˚C. Slides
containing the lateral tegmental area had tyrosine hydroxylase
(TH)- and dopamine β-hydroxylase (DBH)-in situ hybridization
(ISH) performed to assess neuronal loss. Slides containing the
LC had TH-immunohistochemistry (IHC), TH-, and DBH-ISH
performed to assess neuronal loss. Forebrains were either (1) cut
as described above (n= 8) for NET, α1-, and α2-adrenoreceptor
(AR) binding assays or (2) had the frontal cortex (FC), bed
nucleus stria terminalis (BNST)/septum, hippocampus (HP), and
amygdala (Amy) dissected free for measurement of catecholamine
concentrations by high-pressure liquid chromatography (HPLC;
n= 6–7).
Experiment 2: 6OHDA+MPTP study
Forty-three adult male C57Bl/6 mice were purchased from Charles
River Laboratories; 23 mice were administered 6OHDA (10µg/µl)
and 17 mice were administered vehicle (0.2% ascorbic acid/saline)
bilaterally into the LC. Three days later, 11 6OHDA-treated mice
received saline intraperitoneally (IP; two injections 2 h apart;
6OHDA group) while the remaining 15 6OHDA-treated mice
received MPTP (24 mg/kg free base, IP; two injections 2 h apart;
6OHDA+MPTP group). The animals that received vehicle into
the LC were divided into eight mice receiving saline IP (two injec-
tions 2 h apart; control group) and nine mice receiving MPTP
(24 mg/kg free base, IP; two injections 2 h apart; MPTP group).
Three animals from the 6OHDA+MPTP group and one animal
from the MPTP group died within 72 h of the last MPTP injec-
tion. Three weeks after MPTP injection animals were sacrificed
and brains removed. The striatum was dissected free from the
forebrain and catecholamine concentrations were measured uni-
laterally by HPLC for each animal. Midbrain dopaminergic regions
(SN and VTA) and the LC were cut on a cryostat at 16µm onto
Superfrost Plus slides into three sets of slides consisting of alter-
nating sections and stored at−80˚C. Slides containing the SN and
VTA had TH-IHC and TH-ISH performed to assess neuronal loss.
Slides containing the LC had TH-IHC, TH-ISH, and DBH-ISH to
assess the neuronal loss.
TH-IHC
TH-IHC was performed in the SN, VTA, and LC to assess the
number of dopaminergic and noradrenergic neurons as previ-
ously described with the minor modification of adding 0.2%
nickel ammonium sulfate to the DAB visualization step (for
SN and VTA regions only; Szot et al., 2012). The number of
TH-immunoreactive (IR) cell bodies in the SN, VTA, and LC
were counted under 20×magnification in three consecutive atlas
matched sections in the 3-day 6OHDA group and in the four
groups described above to determine if LC neuronal loss enhanced
MPTP-induced damage to dopaminergic neurons. The unilateral
number of TH-IR neurons were averaged for each animal and
data expressed as TH-IR neurons± SEM for each group. Pho-
tomicrographs were taken with a digital camera and imported into
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Adobe Photoshop. To optimize visualization of staining, photomi-
crographs were modified, when necessary, by adjusting brightness
and contrast.
TH- AND DBH-ISH
Tyrosine hydroxylase-immunohistochemistry was performed in
the SN, VTA, and LC and DBH-ISH in the LC as previously
described (Szot et al., 2010, 2012). Briefly, the TH oligonucleotide
probe was a 48 base probe complementary to nucleotides 1351–
1398 of the rat TH mRNA sequence (Grima et al., 1985). The
DBH oligonucleotide probe consisted of two oligonucleotides
complementary to nucleotides 454–505 and 1414–1465 of the
rat sequence (McMahon et al., 1990). The oligonucleotide probes
were 3′ end-labeled with 33P-dATP (PerkinElmer, Boston, MA,
USA) using terminal deoxyribonucleotidyl transferase (Invitro-
gen, Piscataway, NJ, USA). The TH probe contained a range from
0.35 to 0.58× 106 cpm/50µl for the different experiments and was
washed as described in detail in previously published work with
the oligonucleotide (Szot et al., 1997). The DBH probe contained
a range from 0.5 to 2.9× 106 cpm/50µl for the different experi-
ments and washed as described in detail in previously published
work with the oligonucleotide (Szot et al., 2010). Slides contain-
ing the LC region hybridized with either TH or DBH probes were
coated with NTB2 Nuclear Track Emulsion (undiluted; Eastman
Kodak Co., Rochester, NY, USA) and stored at −20˚C for 4 days
for DBH mRNA and 1 week for TH mRNA. Slides containing
the SN/VTA region hybridized with TH probe were coated with
NTB2 Nuclear Track Emulsion (undiluted; Eastman Kodak Co.)
for 1 week. All slides emulsion coated were developed by standard
procedures as previously described (Szot et al., 1997).
Quantitation of TH and DBH mRNA expression was similar
to that performed and described in previous publications (Szot
et al., 2006, 2010) using the MicroComputer Imaging Device Sys-
tem (MCID; InterFocus Imaging, Ltd., Cambridge, England). The
number of positive labeled neurons that achieved labeling three-
fold higher than background was counted bilaterally in all groups
across three atlas matched consecutive sections and averaged for
each animal. Data for the number of positive labeled neurons for
each group were expressed as the average± SEM. The density of
TH and DBH mRNA expression/neuron was performed by mea-
suring the amount of silver grains over cell bodies of labeled neu-
rons that were threefold higher than background under 20× dark-
field illumination using MCID and data for grains/neuron were
expressed as average± SEM for each group. All labeled neurons
that were counted as positively labeled for each oligonucleotide
probe were also quantitated for the amount of TH and DBH
mRNA expression/neuron. Photomicrographs were taken with a
digital camera and imported into Adobe Photoshop. To optimize
visualization of labeling, photomicrographs were modified, when
necessary, by adjusting brightness and contrast.
RECEPTOR BINDING
3H-Nisoxetine (80.0 Ci/mmol; American Radiolabeled Chemi-
cals, St. Louis, MO, USA) was used to quantitate NET binding
sites, 3H-RX821002 (55.0 Ci/mmol; PerkinElmer) was used to
quantitate α2-AR binding sites and 3H-prazosin (83.6 Ci/mmol;
PerkinElmer) was used to quantitate α1-AR binding sites.
Forebrain AR binding studies were performed only in animals
sacrificed 3 days after bilateral LC administration of either vehicle
or 6OHDA. 3H-Nisoxetine binding was performed as previously
described (Weinshenker et al., 2002; Szot et al., 2006, 2010). Briefly,
600µl/slide of incubation buffer (∼3 nM 3H-nisoxetine in 50 mM
Tris buffer with 300 mM NaCl and 5 mM KCl, pH 7.7) was placed
over the tissue. Non-specific binding was defined in the presence
of 1µM mazindol. Slides were incubated for 2 h at room tempera-
ture and then washed twice for 2 min in ice-cold 50 mM Tris buffer,
pH 7.4, dipped in ice-cold distilled water to remove salts and then
dried rapidly under a stream of cool air. 3H-RX821002 binding
was performed as described previously (Szot et al., 2006, 2010).
Briefly, 600µl/slide of incubation buffer (∼2 nM 3H-RX821002
in 50 mM NaPO4 buffer, pH 7.4) was placed over the tissue. Non-
specific binding was defined in the presence of 10µM rauwolscine.
Slides were incubated for 45 min at room temperature and then
washed for 2 min in ice-cold 50 mM NaPO4 buffer, pH 7.4, dipped
in ice-cold distilled water and dried as described above for 3H-
nisoxetine. 3H-Prazosin was performed as described previously
(Sanders et al., 2006; Szot et al., 2006, 2010). Briefly, 600µl/slide
of incubation buffer (∼0.2 nM 3H-prazosin in 50 mM Tris buffer,
1 mM EDTA, pH 7.4) was placed over the tissue. Non-specific
binding was defined in the presence of 10µM phentolamine. Slides
were incubated for 40 min at room temperature, washed and dried
as described above for 3H-nisoxetine. All slides were apposed to
Biomax MR Film (Eastman Kodak Co.) for 2 months.
Films were developed by standard procedures (Szot et al., 1997).
NET, α2- and α1-AR binding sites were quantitated as optical
density (OD) using MCID system in three consecutive sections
atlas matched in control- and 6OHDA-treated groups. NET (3H-
nisoxetine) binding sites were quantitated (OD) in the following
atlas matched regions: FC, septum, BNST, paraventricular thala-
mic nucleus (PVTN), HP, SN, and VTA. α2-AR (3H-RX821002)
binding sites were quantitated in the following atlas matched
regions: FC, septum, BNST, striatum (Str), dorsal thalamic nucleus
(DTN), hypothalamus (hypo), HP, Amy, SN, VTA, and genicu-
late (Gen). α1-AR (3H-prazosin) binding sites were quantitated in
the following atlas matched regions: FC, septum, BNST, thalamus
(Thal), HP, Amy, Hypo, SN, and VTA.
Data for NET, α1-, and α2-AR binding concentrations were
expressed as average (OD)± SEM. Photomicrographs were taken
with a digital camera and imported into Adobe Photoshop. To
optimize visualization of labeling, all photomicrographs were
modified equally, when necessary, by adjusting brightness and
contrast.
HPLC MEASUREMENT OF CATECHOLAMINES IN FOREBRAIN REGIONS
The catecholamine precursor 1-3-4-dihydroxyphenylalanine
(DOPA), the catecholamines norepinephrine (NE) and dopamine
(DA), and the deaminated metabolites of NE and DA dihy-
droxyphenylglycol (DHPG) and dihydroxyphenylacetic acid
(DOPAC) were quantitated in brain tissue extracts by HPLC
with electrochemical detection. Each unilateral brain region (FC,
BNST/septum, HP, and Amy) collected for Experiment 1 and each
unilateral striatal tissue fragment collected for Experiment 2 was
sonicated in 0.5 ml of 0.1 M perchloric acid. A 100-µl aliquot of the
sonicated material was stored at−80˚C for protein determination
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using Pierce BCA™ Protein Assay kit (Thermo Scientific, Rock-
ford, IL, USA). The supernate was collected from centrifugation
of the sonicated material at 13,000× g for 15 min and stored at
−70˚C until catecholamine extraction was performed.
Catecholamines and metabolites were extracted from 100µl
of the sonicated supernate with a modification of the alumina
method of Goldstein et al. (1981). The eluted catechols were
filtered through a 0.22 Millex®GV syringe-driven filter and trans-
ferred to an autosampler tube prior to injection. Detection was
performed with an ESA Coulochem II electrochemical detector
(ESA, Chelmsford, MA, USA) with the conditioning cell set at
+350 mV, electrode 1 of the analytical cell set at +90 mM, and
electrode 2 of the analytical cell set at −300 mV and a Phe-
nomenex reverse phase c18 Gemini column (150 mm× 4.6 , 3 m,
110 Å; Phenomenex, Torrance, CA, USA). The EZChrom Elite™
chromatography data system (Agilent Technologies, Inc., Santa
Clara, CA, USA) was used for data reduction. Catecholamine val-
ues were expressed as mean ng catecholamine/mg protein± SEM
for each group. All samples from each region were assayed for
catecholamines in the same batch in order to reduce variability.
STATISTICAL ANALYSIS
Student’s unpaired t -test was used to assess statistical difference
using GraphPad Prism for Experiment 1. A one-way ANOVA was
used to assess statistical difference followed by a post hoc Tukey’s
test using the computer program GraphPad Prism (v. 5.0, Graph-
Pad Software, Inc.) for Experiment 2. Simple linear regressions
were performed between the number of TH-IR neurons in the LC
to the number of TH-IR neurons in the VTA or SN; number of TH-
IR neurons in the LC to the concentration of each catecholamine
in the striatum; number of TH-IR in the SN to the concentration
of each catecholamine in the striatum, and number of TH-IR neu-
rons in the VTA to the concentration of each catecholamine in the
striatum.
RESULTS
EXPERIMENT 1
Lateral tegmental regions
Three days after bilateral administration of 6OHDA into the LC,
the lateral tegmental area regions, nucleus tract solitaris (NTS),
and A1/A2, were unaffected (data not shown). Both TH and
DBH mRNA expression data in these regions indicate that admin-
istration of 6OHDA directly into the LC does not affect these
noradrenergic neurons as demonstrated previously 3 weeks after
unilateral LC administration of 6OHDA (Szot et al., 2012).
Locus coeruleus
Three days after bilateral administration of 6OHDA into the LC
there was a significant reduction in the number of neurons as
observed by TH-IR (56% reduced), TH mRNA (60% reduced),
and DBH mRNA (77% reduced) expression (Figures 1A,C–E).
The loss of LC neurons as determined by DBH mRNA tended to be
greater than the loss measured by TH-IR and TH-ISH (Figure 1A).
The enhanced loss of LC neurons as determined by DBH mRNA
expression compared to TH mRNA may be due to a 36% decrease
in DBH mRNA expression/neuron that was observed 3 days after
6OHDA (Figures 1B,E). TH mRNA expression/neuron was not
affected by administration of 6OHD into the LC (Figures 1B,D).
Catecholamine concentration in forebrain regions
Bilateral administration of 6OHDA directly into the LC resulted
in a significant loss of NE concentration in the FC (31% reduced),
HP (21% reduced), and Amy (21% reduced) but not in the
BNST/septum compared to vehicle-treated animals (Table 1). In
addition, bilateral administration of 6OHDA directly into the
LC resulted in a significant loss of the NE metabolite DHPG
in all regions studied (FC: 49% reduced; HP: 48% reduced;
BNST/septum: 48% reduced; Amy: 47% reduced; Table 1). Bilat-
eral administration of 6OHDA directly into the LC did not affect
DOPA, DA, or DOPAC concentration in any of the brain regions
studied (Table 1).
A correlation between LC neuronal numbers with cate-
cholamine concentrations in forebrain regions was observed for
DHPG in the FC (r2= 0.41,P = 0.023), HP (r2= 0.48,P = 0.013),
and Amy (r2= 0.56,P = 0.005), but not for NE concentration. The
lack of a correlation for NE to LC neuronal number suggests the
reduction in NE concentration in the FC, HP, and Amy 3 days
after bilateral 6OHDA was less than the loss of LC noradrenergic
neurons.
NET, α1-, and α2-AR binding sites
Bilateral administration of 6OHDA directly into the LC signifi-
cantly reduced NET binding sites in the sep, BNST, PVNT, HP,
and VTA (Figure 2). Interestingly, the number of NET binding
sites in the FC was not significantly different from that in control
animals (13% reduced), but this region did demonstrate a signifi-
cant reduction in NE concentration (31% reduced; Table 1). The
reduction in NET binding sites observed 3 days after administra-
tion of 6OHDA directly into the LC was not as great as observed
3 weeks after 6OHDA (Szot et al., 2012). Bilateral administration
of 6OHDA directly into the LC significantly reduced α2-AR only
in the HP (11% reduced) and Amy (7% reduced; Figure 3). Three
weeks after 6OHDA, α2-AR binding sites were reduced in the HP,
but not in the Amy at this time (Szot et al., 2012). These data sug-
gest that the damage to LC neurons 3 days after 6OHDA had not
extended completely to the terminal regions in the forebrain. Inter-
estingly, administration of 6OHDA significantly increased α1-AR
binding sites in the FC, BNST, Thal, and Gen (Figure 4). This is in
contrast to the effect of 6OHDA 3 weeks later where a reduction in
α1-AR binding sites was observed in the Amy and SN (Szot et al.,
2012).
EXPERIMENT 2
Locus coeruleus
The number of TH-IR neurons in the LC of animals adminis-
tered MPTP was not significantly different from control animals
(Figure 5), indicating that MPTP does not affect the number of
noradrenergic neurons in the LC. However, bilateral LC admin-
istration of 6OHDA resulted in a significant reduction in the
number of TH-IR neurons in the LC as compared to control (36%
reduced) and MPTP (41% reduced)-treated animals, and the addi-
tion of MPTP 3 days after 6OHDA did not further enhance the
reduction induced by 6OHDA (34% reduced compared to control
and 39% reduced compared to MPTP-treated animals; Figure 5).
The effect of 6OHDA on LC neuronal number was variable; the
range of neuronal loss due to 6OHDA with or without MPTP was
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FIGURE 1 | Assessment of LC noradrenergic neuronal number 3 days
after bilateral 6OHDA administration directly into the LC. (A)
Quantitation of LC neuronal number by TH-IR, TH-, and DBH mRNA
expression, (B) quantitation of TH- and DBH mRNA expression/neuron in
LC noradrenergic neurons, and photomicrograph of TH-IR (C), TH mRNA
(D), and DBH mRNA (E) expression 3 days after bilateral vehicle/6OHDA
administration. *Indicates significant difference to vehicle. Scale
bar=200µm.
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Table 1 | Catecholamine levels expressed as ng per catecholamine/mg protein in frontal cortex, BNST/septum, hippocampus, and amygdala
3 days after bilateral administration of vehicle and 60HDA.
Frontal cortex (FC) Hippocampus (HP) BNST/septum Amygdala (amy)
Vehicle 6OHDA Vehicle 6OHDA Vehicle 6OHDA Vehicle 60HDA
DHPG 0.36+0.02 0.18±0.03* 0.17±0.02 0.09±0.01* 0.10±0.02 0.05±0.01* 0.27±0.02 0.14±0.02*
NE 5.33±0.26 3.70±0.12* 4.87±0.30 3.83±0.12* 2.40±0.36 1.69±0.13 4.79+0.26 3.22+0.22*
DOPA 0.05+0.004 0.04±0.004 0.09±0.03 0.07±0.007 0.06±0.007 0.08±0.011 0.03+0.004 0.03+0.003
DA 1.89±0.48 1.12±0.29 0.47±0.08 0.42±0.05 74.9±9.75 82.6±9.14 2.79±0.05 2.93±0.03
DOPAC 1.18+0.17 0.95+0.13 0.26+0.01 0.25+0.03 8.65+1.12 8.68+0.85 0.88+0.08 0.90+0.05
*Indicates significant difference from vehicle animals.
FIGURE 2 | Bilateral LC neuronal loss reduces NET binding sites in
specific forebrain regions 3 days after bilateral vehicle/6OHDA
administration. (A) Quantification of NET binding sites (OD) in control and
6OHDA-treated animals in forebrain regions. *Indicates significant
difference to vehicle. Photomicrographs of NET binding sites at the level of
the septum (B) and HP (C) of vehicle or 6OHDA-treated animal.
∼15–70%. The number of TH- and DBH mRNA positive labeled
neurons in the LC of all four treatment groups is in agreement with
data generated with TH-IR (Figures 6A,B left panels); MPTP had
no effect on the number of TH- and DBH mRNA positive labeled
neurons in the LC, and 6OHDA alone or in combination with
MPTP significantly reduced the number of LC noradrenergic neu-
rons compared to control or MPTP-treated animals (Figures 6A,B
left panels).
The amount of TH mRNA expression/neuron in LC neurons
was not affected by the addition of MPTP or 6OHDA alone,
but the combination of 6OHDA+MPTP resulted in a signifi-
cant reduction (17% reduced) in TH mRNA expression/neuron
compared to control group (Figure 6A right panel). The lack of
an effect of 6OHDA on LC TH mRNA expression/neuron was also
observed 3 days after bilateral 6OHDA (Figure 1B). In contrast,
the amount of DBH mRNA expression/neuron in 6OHDA-treated
animals was significantly reduced 3 weeks later compared to con-
trol (17% reduced), and MPTP-treated (17% reduced) animals
Figure 6B right panel); a response similar to 3 days after 6OHDA
(Figure 1B). The reduction in DBH mRNA expression/neuron
produced by 6OHDA is not enhanced with the administration of
MPTP (20% reduction; Figure 6B right panel). MPTP did not
affect DBH mRNA expression/neuron in the LC (Figure 6B right
panel).
Substantia nigra
The number of TH-IR neurons in the SN of animals adminis-
tered 6OHDA was not significantly different from control animals
(Figure 7), indicating that administration of 6OHDA directly
into the LC did not affect the number of dopaminergic neu-
rons in the SN. However, administration of MPTP resulted in
a significant reduction in the number of SN TH-IR neurons as
compared to control (59% reduced) and 6OHDA-treated animals
(57% reduced), and the addition of MPTP 3 days after 6OHDA
did not alter the reduction induced by MPTP as compared to
control (56% reduced) and 6OHDA (53% reduced)-treated ani-
mals (Figure 7). The effect of MPTP on SN neuronal number was
variable; the range of neuronal loss due to MPTP with or with-
out 6OHDA was ∼30–80%. There was no significant correlation
of LC TH-IR neuronal number with the number of TH-IR neu-
rons in the SN within any group, indicating that LC noradrenergic
neurons did not affect the number of dopaminergic SN neurons.
The number of TH mRNA positive labeled neurons in the SN of
all four treatment groups was in agreement with data generated
with TH-IR (Figure 8); 6OHDA did not significantly affect the
number of SN TH mRNA positive labeled neurons, while MPTP
alone or in combination with 6OHDA significantly reduced the
number of SN dopaminergic neurons compared to control treated
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FIGURE 3 | Bilateral LC neuronal loss reduces α2-AR binding sites in the HP and Amy 3 days later. (A) Quantification of α2-AR binding sites (OD) in control
and 6OHDA-treated animals in forebrain regions and (B) photomicrographs of α2-AR binding in HP and Amy of control and 6OHDA-treated animal. *Indicates
significant difference to vehicle.
FIGURE 4 | Bilateral LC neuronal loss increases α1-AR binding sites in
specific forebrain regions 3 days after bilateral vehicle/6OHDA
administration. (A) Quantification of α1-AR binding sites (OD) in control and
6OHDA-treated animals in forebrain regions and (B) photomicrographs of
α1-AR binding in Ctx, Thal, HP, and Amy of control and 6OHDA-treated
animals. *Indicates significant difference to vehicle.
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FIGURE 5 | Reduced number ofTH-IR neurons in the LC of animals
administered 6OHDA alone and with MPTP compared to control and
MPTP-treated animals. (A) Quantitation of the number of TH-IR neurons
and (B) photomicrographs of TH-IR in the LC of animals which received
saline, MPTP, 6OHDA, and 6OHDA+MPTP. *Indicates significant difference
to control. #Indicates significant difference to MPTP.
animals (MPTP: 71% reduced; 6OHDA+MPTP: 64% reduced) or
6OHDA (MPTP: 69% reduced; 6OHDA+MPTP: 61% reduced;
Figure 8). Prior administration of 6OHDA did not exacerbate
MPTP-induced reduction of the number of TH mRNA positive
labeled neurons in the SN (Figure 8).
The amount of TH mRNA expression/neuron in SN neurons
was not affected by the bilateral LC administration of 6OHDA;
however administration of MPTP alone or with 6OHDA resulted
in a significant reduction in TH mRNA expression/neuron com-
pared to control (MPTP: 31% reduced; 6OHDA+MPTP: 25%
reduced) and 6OHDA-treated animals (MPTP: 42% reduced;
6OHDA+MPTP: 38% reduced; Figure 8). The prior adminis-
tration of 6OHDA to MPTP did not exacerbate MPTP damage on
SN neurons.
Ventral tegmental area
The number of TH-IR neurons in the VTA of animals adminis-
tered 6OHDA was not significantly different from control animals
(Figure 9), indicating that administration of 6OHDA directly
into the LC did not affect the number of dopaminergic neu-
rons in the VTA. However, administration of MPTP resulted
in a significant reduction in the number of TH-IR neurons as
compared to control (44% reduced) and 6OHDA-treated ani-
mals (42% reduced), and the addition of MPTP 3 days after
6OHDA did not alter the reduction induced by MPTP as com-
pared to control (44% reduced) and 6OHDA-treated animals
(41% reduced; Figure 9). The effect of MPTP on VTA neuronal
number was variable; the range of neuronal loss due to MPTP
with or without 6OHDA was ∼15–77%. There was no significant
correlation of LC TH-IR neuronal number with the number of
TH-IR neurons in the VTA within any group, indicating LC neu-
ronal number did not affect dopaminergic neurons in the VTA.
The number of TH mRNA positive labeled neurons in the VTA
in all four groups was in agreement with data generated with
TH-IR (Figure 10 left panel); 6OHDA had no effect on the num-
ber of TH mRNA positive labeled neurons, while MPTP alone
or in combination with 6OHDA significantly reduced the num-
ber of VTA dopaminergic neurons compared to control (MPTP:
64% reduced; 6OHDA+MPTP: 56% reduced) or 6OHDA-treated
animals (MPTP: 67% reduced; 6OHDA+MPTP: 59% reduced;
Figure 10 left panel). Prior administration of 6OHDA did not
exacerbate MPTP-induced reduction of the number of TH mRNA
positive labeled neurons in the VTA (Figure 10 left panel).
The amount of TH mRNA expression/neuron in VTA neu-
rons was not affected by bilateral LC administration of 6OHDA;
however, TH mRNA expression/neuron in VTA neurons was sig-
nificantly reduced in animals administered MPTP compared to
6OHDA-treated animals (23% reduced; Figure 10 right panel).
The effect of MPTP on TH mRNA expression/neuron in VTA is
reversed when 6OHDA is administered prior to MPTP (Figure 10
right panel).
Catecholamine concentrations in striatum
NE concentration in the striatum was not significantly affected
by the administration of MPTP or 6OHDA or the combination
of 6OHDA+MPTP, although there was a trend for a reduc-
tion with the combination of 6OHDA+MPTP (33% reduced).
Interestingly, DHPG concentration (NE metabolite) was signif-
icantly reduced only in the 6OHDA+MPTP-treated animals
compared to control animals (36% reduced; Table 2). DOPA con-
centration in the striatum was significantly reduced in all three
treatment groups compared to control animals (58% reduced
in both MPTP alone and 6OHDA+MPTP, and 33% reduced
in 6OHDA, respectively). In addition DOPA concentration in
6OHDA+MPTP-treated animals was significantly reduced com-
pared to 6OHDA-treated animals (Table 2). DA and its metabolite
DOPAC, were also significantly reduced in all three treatment
groups compared to the control group (MPTP: 91% reduced
DA, 85% reduced DOPAC; 6OHDA: 29% reduced DA, 33%
reduced DOPAC, and 6OHDA+MPTP: 91% reduced DA, 87%
reduced DOPAC). MPTP- and 6OHDA+MPTP-treated ani-
mals were significantly reduced compared to 6OHDA-treated
animals (Table 2). The reduced concentrations of DA and
DOPAC concentration in the striatum resulting from the com-
bined administration of 6OHDA+MPTP were not significantly
different from the DA and DOPAC concentrations of MPTP-
treated animals, reflecting the lack of an effect of LC neu-
ronal loss on MPTP-induced damage on dopaminergic neu-
rons in the SN and VTA. Interestingly, the administration of
6OHDA significantly reduced the concentration of DOPA, DA,
and DOPAC but not NE and DHPG in the striatum indicating
that a loss of noradrenergic neurons indirectly affects striatal DA
concentration.
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FIGURE 6 | Reduced number ofTH and DBH positive labeled neurons
and reduced expression/neuron in the LC of animals administered
6OHDA alone and with MPTP compared to control and MPTP-treated
animals. (A) Quantitation of the number of TH mRNA positive labeled
neurons (left panel) and amount of TH mRNA expression/neuron (right
panel) and (B) quantitation of the number of DBH mRNA positive labeled
neurons (left panel) and amount of DBH mRNA expression/neuron (right
panel) in the LC of animals which received saline, MPTP, 6OHDA, and
6OHDA+MPTP. *Indicates significant difference to control. #Indicates
significant difference to MPTP.
Correlation of LC, SN, and VTA neuronal number to striatal
catecholamine concentration
The number of LC noradrenergic neurons in the control group was
not significantly correlated with any catecholamine concentration
in the striatum (Table 3). In contrast, the number of LC nora-
drenergic neurons in the MPTP, 6OHDA, and 6OHDA+MPTP-
treated groups were significantly correlated with NE and DHPG
in the striatum (Table 3), indicating that when the noradren-
ergic system was compromised, the loss of LC neurons reduces
NE and DHPG concentrations in the striatum. The number of
SN dopaminergic neurons in the control group was not signif-
icantly correlated with any catecholamine concentration in the
striatum (Table 3). The number of SN dopaminergic neurons
in the MPTP-treated group correlated only with striatal DHPG
and NE, indicating a loss of dopaminergic neurons due to MPTP
can influence striatal NE and DHPG concentrations, but not
DA, DOPA, and DOPAC (Table 3). Only when the combina-
tion of 6OHDA+MPTP was administered was there a significant
correlation of the number of SN dopaminergic neurons with
striatal DOPA, DA, and DOPAC, but there was no significant cor-
relation with NE or DHPG (Table 3). The VTA region showed
exactly the same correlations as the SN. The number of VTA
dopaminergic neurons in the control group was not significantly
correlated with any catecholamine concentration in the striatum
(Table 3). The number of VTA dopaminergic neurons in the MPTP
group correlated to striatal DHPG and NE; while the number of
VTA dopaminergic neurons in the 6OHDA+MPTP group corre-
lated with striatal DOPA, DA, and DOPAC. It is interesting to note
that administration of MPTP resulted in a significant correlation
of the number of dopaminergic neurons with the concentrations
of NE and its metabolite in the striatum, but not with DOPA, DA,
or its metabolite DOPAC. Only the combined administration of
6OHDA+MPTP resulted in a significant correlation of dopamin-
ergic neurons in the SN and VTA with striatal concentrations of
DOPA, DA, and DOPAC.
DISCUSSION
THREE DAYS AFTER 6OHDA THERE IS A SIGNIFICANT LOSS OF LC
NEURONS AND TERMINALS
The focus of this study is to determine if the loss of LC noradrener-
gic neurons can enhance the damage of a dopaminergic neurotoxin
on dopaminergic neurons. To assess if LC loss can enhance dam-
age to dopaminergic neurons, MPTP is administered 3 days after
bilateral administration of 6OHDA directly into the LC. At the
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time MPTP is administered, the effects of 6OHDA are restricted
to LC neurons, no effect on noradrenergic lateral tegmental neu-
rons and dopaminergic neurons is observed; results similar to data
generated 3 weeks after 6OHDA (Figures 7–10; Szot et al., 2012).
Three days after bilateral 6OHDA there is a significant reduction
FIGURE 7 | Reduced number ofTH-IR neurons in the SN of animals
administered MPTP alone and with 6OHDA compared to control and
6OHD-treated animals. (A) Quantitation of the number of TH-IR neurons
and (B) photomicrographs of TH-IR in the SN of animals which received
saline, MPTP, 6OHDA, and 6OHDA+MPTP. *Indicates significant difference
to control. #Indicates significant difference to 6OHDA.
in: (1) the number of LC noradrenergic neurons as observed by
TH-IR, TH-, and DBH mRNA expression; (2) DBH mRNA expres-
sion/neuron; (3) DHPG and NE concentration in the FC, HP, and
Amy, with no effect on DOPA, DA, and DOPAC; and (4) NET
and α2-AR binding sites in forebrain regions; results again simi-
lar to what is observed 3 weeks after 6OHDA (Figure 5; Tables 1
and 2; Szot et al., 2012). However, the reduction in many of these
noradrenergic markers in forebrain regions 3 days after bilateral
6OHDA is less than that observed 3 weeks after unilateral 6OHDA
(Szot et al., 2012), suggesting that 3 days after 6OHDA the LC
terminals are not affected to the same degree as the loss of LC
neurons. This hypothesis is supported by a lack of a significant
correlation 3 days after 6OHDA of LC neuronal number with NE
concentrations in the FC, HP, and Amy. Interestingly, 3 days after
6OHDA α1-AR binding sites are significantly elevated in the FC,
BNST, Thal, and Gen; while 3 weeks after unilateral 6OHDA there
is a significant loss of α1-AR in the Amy and SN. Though NE con-
centrations are not measured in the SN/VTA region 3 days after
bilateral 6OHDA administration, data from 3 weeks after unilat-
eral 6OHDA suggests that this region 3 days after 6OHDA may also
have reduced NE concentration (Szot et al., 2010, 2012). There-
fore when MPTP is administered 3 days after 6OHDA, there is a
significant loss of LC neurons (60% reduced) and innervation to
forebrain regions is compromised.
ADMINISTRATION OF MPTP AFFECTS NORADRENERGIC NEURONS
AND 6OHDA AFFECTS DOPAMINERGIC NEURONS
Administration of MPTP significantly reduces the number of SN
and VTA dopaminergic neurons (greater effect on SN neurons
than VTA neurons) and decreases TH mRNA expression/neuron
in dopaminergic neurons of the SN. MPTP also reduces striatal
DOPA, DA, and DOPAC concentrations, supporting the selec-
tivity of MPTP to dopaminergic neurons. These changes in the
dopaminergic nervous system have been reported numerous times
in mice and these changes have been observed in dopaminergic
FIGURE 8 | Reduced number ofTH positive labeled neurons and
reducedTH mRNA expression/neuron in the SN of animals
administered MPTP alone and with 6OHDA compared to control and
6OHDA-treated animals. Quantitation of the number of TH mRNA
positive labeled neurons (left panel) and amount of TH mRNA
expression/neuron (right panel) in the SN of animals which received saline,
MPTP, 6OHDA, and 6OHDA+MPTP. *Indicates significant difference to
control. #Indicates significant difference to 6OHDA.
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neurons of postmortem PD subjects (Heikkila et al., 1984; Javoy-
Agid et al., 1990; Kastner et al., 1993; Jackson-Lewis et al., 1995;
Jakowec et al., 2004; Nagatsu and Sawada, 2007). Interestingly,
the number of SN or VTA neurons following MPTP treatment
does not correlate with DA, DOPA, or DOPAC concentrations
in the striatum (Table 3), suggesting some other factor may
be influencing the dopaminergic neurons and/or DA concen-
tration in the striatum. Previous work has demonstrated that
MPTP in mice has a more dramatic effect on striatal DA lev-
els than on dopaminergic neurons because it has been hypoth-
esized that MPTP initially affects dopaminergic terminals and
with time the effect of MPTP on terminals may be reversed
(Heikkila et al., 1984; Perry et al., 1985; Donnan et al., 1986;
Ricaurte et al., 1986; Jackson-Lewis et al., 1995; Bezard et al.,
2000; Jakowec et al., 2004). This effect of MPTP at dopaminer-
gic terminals may explain the lack of a correlation between SN
and VTA neuronal number to striatal DOPA, DA, and DOPAC
concentrations.
MPTP does not significantly affect the number of LC nora-
drenergic neurons as measured by TH-IR, and TH and DBH
mRNA expression, and it does not affect the expression/neuron
of TH and DBH mRNA in LC neurons. Consequently, there
is not a significant effect of MPTP on striatal DHPG and NE
concentrations. Interestingly though, in the MPTP-treated ani-
mals NE and DHPG concentrations in the striatum are sig-
nificantly correlated with SN and VTA neurons. The reduction
in DOPA concentration due to MPTP could result in reduced
NE concentration in the striatum because DOPA is also a pre-
cursor for NE, but as described above, MPTP-induced loss of
SN and VTA neurons does not correlate with DOPA concen-
tration in the striatum. Therefore, the correlation of SN and
VTA dopaminergic neurons following MPTP treatment could
not result in reduced striatal NE and DHPG levels. Dopamin-
ergic neurons in the SN and VTA have been shown to inner-
vate the LC (MacRae-Degueurce and Milon, 1983); therefore, the
effect of MPTP on NE and DHPG concentrations in the stria-
tum may be due to lower basal firing rate of LC neurons when
dopaminergic neuronal numbers are reduced (Miguelez et al.,
2011).
The loss of LC noradrenergic neurons does not affect the num-
ber of dopaminergic neurons in the SN or VTA as described
above or in previously published work (Szot et al., 2012),
but the loss of LC noradrenergic neurons does reduce DA,
DOPA, and DOPAC concentrations in the striatum, which also
has been shown previously (Lategan et al., 1990, 1992). LC
neurons innervate dopaminergic neurons in the SN and VTA
(Swanson and Hartman, 1975; Jones and Moore, 1977; Phillip-
son, 1979; Simon et al., 1979; Jones and Yang, 1985; Fritschy
and Grzanna, 1990; Szot et al., 2012); and a reduction in LC
neurons reduces the activity of dopaminergic neurons (Gren-
hoff and Svensson, 1989, 1993; Grenhoff et al., 1993, 1995;
Guiard et al., 2008; Wang et al., 2010). This effect is medi-
ated by dopamine D2 receptors, not α1- or α2-ARs (Arencibia-
Albite et al., 2007). The reduced activity of dopaminergic neu-
rons as a result of LC neuronal loss and innervation could
result in reduced DA, DOPA, and DOPAC concentration in the
striatum.
FIGURE 9 | Reduced number ofTH-IR neurons in the VTA of animals
administered MPTP alone and with 6OHDA compared to control and
6OHD-treated animals. (A) Quantitation of the number of TH-IR neurons
and (B) photomicrographs of TH-IR in the VTA of animals which received
saline, MPTP, 6OHDA, and 6OHDA+MPTP. *Indicates significant difference
to control. #Indicates significant difference to 6OHDA.
COMBINATION OF 6OHDA+MPTP DOES NOT ENHANCE SN AND VTA
NEURONAL LOSS OR STRIATAL DA CONCENTRATION, BUT IT DOES
RESULT IN A CORRELATION OF SN AND VTA NEURONS TO STRIATAL
DOPA, DA, AND DOPAC CONCENTRATION
The administration of MPTP after 6OHDA did not affect the
loss of LC noradrenergic neurons compared to 6OHDA, but the
combination of 6OHDA+MPTP did result in a significant reduc-
tion of TH mRNA expression/neuron in surviving LC neurons and
striatal DHPG concentration (NE metabolite) compared to con-
trol animals. The reduction in TH mRNA expression/neuron in
6OHDA+MPTP animals may be the reason for the reduction in
striatal DHPG concentration. NE concentration in the striatum of
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FIGURE 10 | Reduced number ofTH positive labeled neurons and
reducedTH mRNA expression/neuron in the VTA of animals
administered MPTP alone and with 6OHDA compared to control and
6OHD-treated animals. Quantitation of the number of TH mRNA positive
labeled neurons (left panel) and amount of TH mRNA expression/neuron
(right panel) in the VTA of animals which received saline, MPTP, 6OHDA,
and 6OHDA+MPTP. *Indicates significant difference to control. #Indicates
significant difference to 6OHDA.
Table 2 | Catecholamine levels expressed as ng per catecholamine/mg protein in striatum of control, MPTP alone, 6OHDA alone, and
6OHDA+MPTP-treated animals.
Group DHPG NE DOPA DA DOPAC
Control 0.11±0.008 1.62±0.19 0.12±0.02 122.3±9.7 13.5±1.3
MPTP 0.09±0.009 1.52±1.6 0.05±0.006* 11.3±2.7*# 2.0±0.4 *#
60HDA 0.09±0.008 1.48±0.15 0.08±0.007* 87.0±5.2* 9.0±0.74*
60HDA+MPTP 0.07±0.007* 1.09±0.12 0.05±0.003*# 10.9±1.5*# 1.8±0.23*#
*Indicates significant difference from control animals.
#Indicates significant difference from 60HDA alone animals.
6OHDA+MPTP is reduced compared to control animals (33%
reduced), but it did not reach statistical significance. The num-
ber of LC noradrenergic neurons in the 6OHDA+MPTP group
was highly correlated with striatal NE and DHPG concentration,
similar to 6OHDA-treated group.
In contrast to previously published work (Mavridis et al., 1991;
Marien et al., 1993; Bing et al., 1994; Fornai et al., 1996, 1997; Srini-
vasan and Schmidt, 2003, 2004; Archer and Fredriksson, 2006) the
dosing paradigm of 6OHDA and MPTP outlined in this study did
not enhance the loss of dopaminergic neurons in the SN and VTA
or further reduce the concentration of DOPA, DA, or DOPAC
in the striatum, despite the striatal reduction of DA, DOPA, and
DOPAC by 6OHDA alone. This is the only study to date that mea-
sures neuronal numbers in the LC, SN, and VTA in conjunction
with striatal catecholamine levels. The lack of effect of LC loss
on MPTP-induced dopaminergic damage may be that the reduc-
tion of NE concentration at the time MPTP was administered is
not severe enough, 3 days following 6OHDA NE loss in forebrain
regions is moderate (20% reduced in HP, 30% reduced in FC, and
33% in Amy). The 3-day time was chosen for this study because
it falls in the middle of the times used in these previous pub-
lished studies (same day – 3 weeks) where enhanced damage to
dopaminergic neurons was observed following the administration
of a noradrenergic neurotoxin (Mavridis et al., 1991; Marien et al.,
1993; Bing et al., 1994; Fornai et al., 1995, 1996, 1997; Srinivasan
and Schmidt, 2003, 2004; Archer and Fredriksson, 2006). It is dif-
ficult to know exactly how severe a loss of NE concentration was in
forebrain regions of these published studies when the dopaminer-
gic neurotoxin was administered because the majority of these
studies did not assess alterations in the noradrenergic system.
However, the enhanced effect of a noradrenergic neurotoxin on
dopaminergic damage by a dopaminergic neurotoxin can not be
due solely to reduced forebrain NE concentration because in two
of the studies, MPTP was administered too close in time (same
time or 24 h later) to the noradrenergic neurotoxin (6OHDA in
LC and DSP4; Mavridis et al., 1991; Marien et al., 1993) for their
to be reduced NE concentration in the forebrain. In addition,
administration of MPTP to the Dbh knockout mice, which are
unable to synthesize NE (Thomas et al., 1998), does not enhance
MPTP-induced damage (Rommelfanger and Weinshenker, 2007);
therefore, concentration of NE in forebrain regions does not
appear to be an influence in mediating the enhanced damage
induced by MPTP. Loss of LC noradrenergic neurons and inner-
vation may be an influencing factor in mediating the enhanced
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Table 3 | Correlation between the number ofTH-IR neurons in the LC, SN, and VTA to striatal catecholamine concentration.
Region/treatment DHPG NE DOPA DA DOPAC
LC #/Control P =0.62 P =0.84 P =0.21 P =0.94 P =0.14
r2=0.018 r2=0.003 r2=0.11 r2=0.0005 r2=0.15
LC #/MPTP P =0.047* P =0.037* P =0.56 P =0.99 P =0.81
r2=0.25 r2=0.28 r2=0.03 r2=5×10−6 r2=0.004
LC #/60HDA p=0.001* P =0.0008* P =0.23 P =0.11 P =0.24
r2=0.42 r*=0.44 r2=0.06 r2=0.12 r2=0.07
LC #/60HDA+MPTP P =0.002* P =0.002* P =0.49 P =0.77 P =0.71
r2=0.48 r2=0.35 r2=0.02 r2=0.004 r2=0.006
SN #/Control P =0.90 P =0.92 P =0.54 P =0.97 P =0.74
r2=0.001 r2=0.0008 r2=0.03 r2=0.0001 r2=0.003
SN #/MPTP p=0.01* P =0.042* P =0.76 P =0.28 P =0.09
r2=0.39 r2=0.26 r2=0.007 r2=0.08 r2=0.19
SN #/60HDA P =0.47 P =0.23 P =0.45 P =0.76 P =0.94
r2=0.03 r2=0.08 r2=0.03 r2=0.005 r2=0.0003
SN #60HDA+MPTP P =0.97 P =0.92 P =0.002* P =0.0009* p=0.001*
r2=6×10−5 r2=0.0004 r2=0.36 r2=0.41 r2=0.39
VTA #/Control P =0.54 P =0.65 P =0.09 P =0.69 P =0.43
r2=0.03 r2=0.02 r2=0.19 r2=0.012 r2=0.06
VTA #/MPTP P =0.024* P =0.022* P =0.35 P =0.09 P =0.06
r2=0.31 r2=0.32 r2=0.06 r2=0.19 r2=0.24
VTA #/60HDA P =0.18 P =0.71 P =0.55 P =0.69 P =0.79
r2=0.10 r2=0.008 r2=0.02 r2=0.009 r2=0.004
VTA #/60HDA+MPTP P =0.52 P =0.21 P =0.017* P =0.0002* P =0.0012*
r2=0.02 r2=0.07 r2=0.23 r2=0.48 r2=0.39
damage of dopaminergic neurotoxins; however this study indi-
cates that the reduced number of LC noradrenergic neurons after
6OHDA+MPTP does not correlate with the reduced number
of SN or VTA neurons, indicating the degree of LC neuronal
loss does not influence the number of dopaminergic neurons.
Previous work demonstrating enhanced dopaminergic damage
did not assess LC neuronal loss to dopaminergic neurons after
dopaminergic neurotoxin.
Interestingly, the combination of 6OHDA+MPTP did result in
a significant correlation between the number of SN and VTA neu-
rons to striatal DOPA, DA, and DOPAC concentration, a response
not observed with MPTP alone. The significant correlation of
SN and VTA neuronal number after MPTP to striatal NE and
DHPG concentration is lost when 6OHDA is administered prior
to the administration of MPTP. It is unclear why the combi-
nation of LC neuronal loss before dopaminergic neuronal loss
results in a correlation between dopaminergic neuronal numbers
to striatal DOPA, DA, and DOPAC concentrations. Even though
MPTP significantly reduces striatal DA concentration, mice do
not exhibit motor deficits that are observed in humans. When
noradrenergic neurons are reduced in monkey models of PD, the
motor deficits observed with MPTP are more severe and persis-
tent (Mavridis et al., 1991; Alexander et al., 1992). These data
indicate that the loss of LC noradrenergic neurons is an impor-
tant aspect of PD. Rommelfanger et al. (2007) showed that Dbh
knockout mice were profoundly impaired on most motor tests,
but an 80% loss of striatal DA in mice does not result in motor
deficits.
SUMMARY
The loss of LC neurons and forebrain innervation prior to the
administration of MPTP does not result in an enhanced loss of
dopaminergic neurons in the SN and VTA or DA concentration in
the striatum. However, when 6OHDA and MPTP are sequentially
administered to animals a correlation now exists between SN and
VTA neuronal number with striatal DA. This may occur because
administration of 6OHDA or MPTP alone can affect the function
of the other region’s neurons. 6OHDA induced LC neuronal loss
results in reduced DOPA, DA, and DOPAC in the striatum but
does not affect NE and DHPG. MPTP alone does not significantly
reduce NE or DHPG, but the combination of 6OHDA+MPTP
significantly reduces LC TH mRNA expression/neuron and striatal
DHPG concentration. In PD, the interaction between noradren-
ergic and dopaminergic regions is altered due to neuronal loss
in both regions, and this altered interaction may influence the
efficacy of pharmacological treatment of PD. Recently, Barnum
et al. (2012) demonstrated a difference in the response of rats
to L-DOPA therapy between animals that had only a dopamin-
ergic lesion to animals with a noradrenergic and dopaminergic
lesion. These results indicate that the loss of LC and SN/VTA neu-
rons in PD affect the function of the surviving neurons in the
alternate region; therefore, exploring this interaction will aid in
understanding PD.
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